Catalyst Brief

← Calendar

Readoutin 104d

Viatris Innovation GmbH — Cenerimod

Phase 3 primary completion: A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus.

Date
Mar 2027
Type
Readout
Indication
Lupus Erythematosus, Systemic

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Viatris Innovation GmbH

  1. Dec2026